Diabetes Clinical Trials in Provo
View 44 new treatments for Diabetes in Provo, UT. Every day, Power helps hundreds of Diabetes patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
ILUVIEN® Implant for Diabetic Macular Edema
Alimera Sciences Clinic, Salt Lake City + 1 more
This is a randomized, masked, active-controlled, parallel-group, multi-center study that will assess the efficacy of ILUVIEN as a baseline therapy in the treatment of Center Involving DME (CI-DME). The study will enroll patients who are either treatment naïve or have not received any DME treatments for the preceding 12 months as documented in medical records. Patients who received DME treatment \>12 months before screening, must not have received \>4 intravitreal injections. The study will compare 2 treatment regimens: ILUVIEN intravitreal implant (0.19 mg) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL), compared to intravitreal aflibercept loading dose (2 mg administered by intravitreal injection every 4 weeks for 5 consecutive doses) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL).Show More
Waitlist
No Placebo Trial
Phase 4
Est. 5 - 8 Weeks
Samer Kaba, MD
Study Chair
Metformin for Prediabetes
Research Clinic, Salt Lake City + 1 more
This trial is testing whether metformin can lower the risk of death, heart attacks, and strokes in people with pre-diabetes and heart or blood vessel issues. Metformin is a drug that helps control blood sugar levels and has been used to treat type 2 diabetes mellitus for more than 60 years. The study involves patients who have pre-diabetes and existing heart or blood vessel problems, aiming to see if metformin can provide additional health benefits.Show More
Recruiting
Phase 4
Est. 5 - 8 Weeks
Gregory G. Schwartz, PhD MD
Study Chair
Rifampin for Osteomyelitis in Diabetics
Research Clinic, Salt Lake City + 1 more
The purpose of this research study is to determine if rifampin, an antibiotic (a medicine that treats infections), is effective in treating osteomyelitis (infection of the bone) of the foot in diabetic patients. Despite use of powerful antibiotics prescribed over a long period of time, many diabetic patients remain at a high risk for needing an amputation of part of the foot or lower leg because the osteomyelitis is not cured. Some small research studies have shown that addition of rifampin to other antibiotics is effective in treating osteomyelitis in both diabetics and non-diabetics. However, because few diabetics with osteomyelitis have been studied, there is no definite proof that it is better than the usual treatments for diabetic patients. If this study finds that adding rifampin to the usual antibiotics prescribed for osteomyelitis reduces the risk for amputations, doctors will be able to more effectively treat many Veteran patients with this serious infection. Improving treatment outcomes is an important healthcare goal of the VA.Show More
Recruiting
Phase 4
Est. 3 - 12 Weeks
Mary T Bessesen, MD
Study Chair
Naltrexone + Bupropion for Obesity
Currax Clinic, West Jordan + 1 more
This trial studies the effects of a medication combination (naltrexone and bupropion) on heart health. It targets patients to see if this treatment increases the risk of major heart problems. The study also includes advice on diet and exercise. Naltrexone and bupropion have been used in combination for weight loss, but they have been associated with various adverse effects, including neuropsychiatric disorders and cardiovascular risks.Show More
Recruiting
Phase 4
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Infliximab Optimization for Crohn's Disease
Research Clinic, Salt Lake City + 1 more
This trial tests if using a computer program to decide infliximab doses is better and safer than standard dosing for patients with inflammatory bowel disease. The program helps doctors choose the best dose by looking at individual health details, aiming to keep the medication working well and prevent the disease from getting worse. Infliximab is commonly used to treat inflammatory bowel disease, and dose optimization has been shown to improve treatment outcomes.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Pentoxifylline for Diabetic Kidney Disease
Research Clinic, Salt Lake City + 1 more
Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.Show More
Recruiting
Phase 4
Est. 6 - 12 Weeks
David J Leehey
Study Chair
Ranibizumab PDS Implant for Diabetic Retinopathy
Hoffmann-La Roche Clinic, Salt Lake City + 2 more
Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the Efficacy, Safety of the Port Delivery System with Ranibizumab (PDS) Relative to the Comparator ArmShow More
Waitlist
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Clinical Trials
Study Director
Semaglutide for Diabetic Eye Disease
Novo Nordisk Clinic, Murray + 2 more
This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. The study will last for 5 years.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Clinical Reporting Anchor and Disclosure (1452)
Study Director
Retatrutide for Type 2 Diabetes
Eli Lilly Clinic, Sandy + 1 more
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Semaglutide + Low-Dose Insulin Glargine for Type 2 Diabetes
Novo Nordisk Clinic, Salt Lake City + 1 more
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home visit. Participants will be asked to wear a sensor that measures their blood sugar all the time in 2 periods of 10 days during the study.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
Clinical Transparency (dept. 2834)
Study Director
Page 1 of 6
Frequently Asked Questions
Explore related conditions